Overall, LAT1, ASCT2, and xCT are overexpressed through oncogenic, hypoxic, and epigenetic programs, support metabolic and redox demands, and predict poor outcomes, thereby establishing them as both biomarkers and therapeutic targets in NSCLC. The gene discussed is SLC1A5; the disease is non-small cell lung carcinoma.